Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans’ Trips And More
Welcome to Benzinga’s psychedelic headlines roundup. This is our pick of must-read news items from the first two…
Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More
Welcome to Benzinga’s psychedelic headlines roundup. This is our pick of must-read news items from the last two…
Psychedelics Headlines: Trauma-Informed Care, Valentine’s Day & MDMA, Academics On Drugs And More
Welcome to Benzinga’s psychedelics headlines roundup. This is our pick of must-read news items concerning the last few…
‘Rainforests Are Nature’s Medicine Cabinets’: Biotech Co. Performs Fresh Research On Traditional Plants For Modern Mental Health Challenges
Numerous companies in the psychedelics industry are essentially advancing research on compounds that have a history of past…
Psychedelics Headlines: Anti-inflammatory Effects, Global Drug Survey, ‘Synthetic Surprise,’ UK’s Harm Reduction Hub And More
Discover the latest research on psychedelics, from anti-inflammatory effects to end-of-life therapy. New journal issue and online course available.
Psyched: Biden Approves Psychedelics Trials, RFK, Australia’s First Legal Dedicated Clinic & More
President Biden Approves Psychedelics Clinical Trials For Active Military Members
President Biden signed into law the 2024 National Defense Authorization Act (NDAA), large-scale legislation that also contains a mandate to fund clinical trials with psychedelics for active service members.
Psyched: Steve Cohen Goes Big On Cybin, Fed Intervention On Psilocybin, Ketamine Insurance And More
Billionaire Steve Cohen Buys 19M Shares Of Cybin Stock For Psychedelics R&D, Blake Mycoskie $100M Pledge
Peru’s Coca Leaf Will Be Used For Research Toward Treating ADHD, Learn The Details
Magdalena Biosciences, Jaguar Health (NASDAQ: JAGX) and Filament Health (OTCQB: FLHLF)
Filament Health and Jaguar Health’s Joint Venture Completes Successful Import of Coca Leaf for Psychedelic Research
Filament Health Corp. (OTCQB:FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or "Filament Health"), a clinical-stage natural psychedelic drug development company, today announced
Psilocybin Therapy Trials: Gambling Addiction Study, Opioid Pain & Alcohol Addiction Trials
Starting this October, scientists at Imperial College London’s (ICL) Centre for Psychedelic Research will assess psilocybin-assisted therapy for gambling addiction, noted Psychedelic Spotlight.